Teva price target raised to $16 from $15 at UBS

UBS analyst Ashwani Verma raised the firm’s price target on Teva to $16 from $15 and keeps a Buy rating on the shares. The firm has further conviction in its bull thesis post-Q4, and sees the improving base business growth narrative driving upside in the first half of the year, while Teva’s pipeline can drive outperformance in the second half, the analyst tells investors in a research note.